• Sterilizing Grade Filtration Unit Operations For Plasmid DNA Processes

    The large size of pDNA can present a challenge for sterile filtration unit operations within your gene therapy manufacturing since the product can be retained by the filters, leading to both yield loss and low filtration capacity. Optimization of a sterilized grade filtration unit can help increase yield and filtration capacity. Read on to learn more!

  • Chromatographic Purification Of Plasmid DNA

    Widespread application of pDNA in gene therapy is driving increased demand and as a response, plasmid manufacturing must become more efficient with improved productivity. Intensification of chromatographic steps can help address this demand and has led to an exploration of the use of convective media (monoliths, membranes, fibre based technologies).

  • Ensuring Viral Vector Supply For Gene Therapies

    The rapid success of gene therapies also brings with it a number of challenges, the most significant being ensuring a sufficient viral vector supply, despite shortened development timelines. This infographic demonstrates how cells grown in suspension are much better suited for large-scale production of viral vectors, what to consider in order to successfully scale-up your viral vector production, including the challenges faced in upstream upscaling, and a specific solution we’ve developed to help you address these challenges.

  • Have Confidence In Your Bio/Pharma Data

    The pharmaceutical industry has grown from simple aspirins to IV delivery, antibiotics and, most recently, cell and gene therapy. Products are more complex, tailored and varied than ever and the associated amount of data is growing - which requires a new level of attention to detail. Learn what features tolook for when choosing a data management system to establish compliant data visibility across teams, sites and partners and establish data integrity throughout the product life cycle.

  • Gene Therapy Development Crosses A Digital Divide

    Mainframe to digital: NeuBase Therapeutics Chairman, CEO, & Founder Dietrich A. Stephan, Ph.D. says we’ve reached a digitally-enabled inflection point in disease therapy development, and that we're making rapid progress aided by big data and machine learning.

  • Toronto Accelerator Fosters Made-In-Canada Approach To Cell Therapy

    Through contract manufacturing and investment, CCRM aims to realize economic and health benefits of technologies that use living cells to cure and treat diseases.

  • Boost Cys-Solubility, Performance In Cell Culture Media Apps

    While the solubility of free L-Cysteine is high at neutral pH, the applicable concentration in basal and feed media is limited. Read more about an available solution for solubility and performance challenges.

  • Covid-19 Impact On Bioprocessing: PART 3 Long-Term Changes Resulting From The Pandemic

    Changes in the bio/pharmaceutical industry are being accelerated and catalyzed by the responses to the current Covid-19 pandemic. Although suppliers have proven themselves rather robust in their dealing with the pandemic, and business is continuing generally uninterrupted, there will be significant changes.

  • Product Development For An Oral Solid Dosage Using Continuous Manufacturing

    A thorough evaluation using several small-scale studies should be completed to help determine whether continuous or batch manufacturing is the best fit for your product.

  • GenCure Selects G-Con Pre-Fabricated Cleanroom PODS For Flexibility And Project Timelines

    GenCure, a subsidiary of San Antonio-based nonprofit BioBridge Global, enables progress in the field of advanced therapies by offering process and analytical development, cGMP manufacturing, and in-process and release testing.